Cross-activating c-Met/?1 integrin complex drives metastasis and invasive resistance in cancer.

ABSTRACT: The molecular underpinnings of invasion, a hallmark of cancer, have been defined in terms of individual mediators but crucial interactions between these mediators remain undefined. In xenograft models and patient specimens, we identified a c-Met/?1 integrin complex that formed during significant invasive oncologic processes: breast cancer metastases and glioblastoma invasive resistance to antiangiogenic VEGF neutralizing antibody, bevacizumab. Inducing c-Met/?1 complex formation through an engineered inducible heterodimerization system promoted features crucial to overcoming stressors during metastases or antiangiogenic therapy: migration in the primary site, survival under hypoxia, and extravasation out of circulation. c-Met/?1 complex formation was up-regulated by hypoxia, while VEGF binding VEGFR2 sequestered c-Met and ?1 integrin, preventing their binding. Complex formation promoted ligand-independent receptor activation, with integrin-linked kinase phosphorylating c-Met and crystallography revealing the c-Met/?1 complex to maintain the high-affinity ?1 integrin conformation. Site-directed mutagenesis verified the necessity for c-Met/?1 binding of amino acids predicted by crystallography to mediate their extracellular interaction. Far-Western blotting and sequential immunoprecipitation revealed that c-Met displaced ?5 integrin from ?1 integrin, creating a complex with much greater affinity for fibronectin (FN) than ?5?1. Thus, tumor cells adapt to microenvironmental stressors induced by metastases or bevacizumab by coopting receptors, which normally promote both cell migration modes: chemotaxis, movement toward concentrations of environmental chemoattractants, and haptotaxis, movement controlled by the relative strengths of peripheral adhesions. Tumor cells then redirect these receptors away from their conventional binding partners, forming a powerful structural c-Met/?1 complex whose ligand-independent cross-activation and robust affinity for FN drive invasive oncologic processes.

SUBMITTER: Jahangiri A 

PROVIDER: S-EPMC5642678 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature